Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat

Chiavegato, Angela; Bollini, Sveva; Pozzobon, Michela; Callegari, A.; Gasparotto, Lisa; Taiani, Jenny; Piccoli, Martina; Lenzini, Elisabetta; Gerosa, Gino; Vendramin, Igor; Cozzi, Emanuele; Angelini, Annalisa; Iop, Laura; Zanon, Giovanni Franco; Atala, Anthony; Coppi, Paolo De; Sartore, Saverio

doi:10.1016/j.yjmcc.2006.12.008

Cited by 134 publications

(143 citation statements)

References 31 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Similar to our observations, others using the same cell lines, also found an intense immunorejection response after hAFS transplantation into the immunosuppressed and immunodefi cient rat myocardium [28]. Although hAFS cells were originally thought to be non-immunogenic because of their lack in major histocompatibility complex class II molecules, there is now evidence for expression of T-cell co-stimulatory molecules (normally found on antigen presenting cells) that may contribute to their immunorejection after transplantation [28]. Possibly, as a result of the relative immaturity of the newborn immune system, these molecules are less effective thereby allowing the survival of transplanted hAFS cells into the perinatal brain [17]).…”

Section: Nstnandhnasupporting

confidence: 92%

“…This rejection response occurred despite the immunosuppression of rats with Cyclosporin A using a regimen that has successfully supported the long-term survival of other xenotransplanted human stem cells [3,6,14]. Similar to our observations, others using the same cell lines, also found an intense immunorejection response after hAFS transplantation into the immunosuppressed and immunodefi cient rat myocardium [28]. Although hAFS cells were originally thought to be non-immunogenic because of their lack in major histocompatibility complex class II molecules, there is now evidence for expression of T-cell co-stimulatory molecules (normally found on antigen presenting cells) that may contribute to their immunorejection after transplantation [28].…”

Section: Nstnandhnasupporting

confidence: 87%

See 1 more Smart Citation

Human Amniotic Fluid Stem Cells Do Not Differentiate Into Dopamine Neurons In Vitro or After Transplantation In Vivo

Donaldson

Cai

Yang

et al. 2009

Stem Cells and Development

View full text Add to dashboard Cite

Section: Nstnandhnasupporting

confidence: 92%

Section: Nstnandhnasupporting

confidence: 87%

Human Amniotic Fluid Stem Cells Do Not Differentiate Into Dopamine Neurons In Vitro or After Transplantation In Vivo

Donaldson

Cai

Yang

et al. 2009

Stem Cells and Development

View full text Add to dashboard Cite

“…AFS cells [49,65] hAF The source where the cells are derived from, cell surface phenotype, TF expression profile, and differentiation potential are shown. That cells with MAPC properties may be (in part) generated in vitro comes from a study by Anjos-Afonso and Bonnet, who demonstrated that when SSEA1 þ cells isolated from fresh Lin/CD45/CD31 neg BM cells were cultured under MAPC conditions, expression of Oct4, Nanog, and Rex1, present at low levels in the freshly isolated cells, increased significantly.…”

Section: Can In Vitro Culture Convert Germline Stem/progenitor Cells mentioning

confidence: 99%

Concise Review: Culture Mediated Changes in Fate and/or Potency of Stem Cells

2011

View full text Add to dashboard Cite

Although Gurdon demonstrated already in 1958 that the nucleus of intestinal epithelial cells could be reprogrammed to give rise to adult frogs, the field of cellular reprogramming has only recently come of age with the description by Takahashi and Yamanaka in 2006, which defined transcription factors can reprogram fibroblasts to an embryonic stem cell-like fate. With the mounting interest in the use of human pluripotent stem cells and culture-expanded somatic stem/progenitor cells, such as mesenchymal stem cells, increasing attention has been given to the effect of changes in the in vitro microenvironment on the fate of stem cells. These studies have demonstrated that changes in culture conditions may change the potency of pluripotent stem cells or reprogram adult stem/progenitor cells to endow them with a broader differentiation potential. The mechanisms underlying these fate and potency changes by ex vivo culture should be further investigated and considered when designing clinical therapies with stem/progenitor cells. STEM CELLS

show abstract

“…Although recently many reports depicted that stem cells such as c-kit positive [23], sca-1 positive cells [77], Human Amniotic Fluid Stem Cells (hAFSC) [78], Adipocyte Derived Stem Cells [79], Cardiospheres [80], or Figure 2. Mechanisms of stem cell therapy for heart failure.…”

Section: Pluripotent Stem Cellsmentioning

confidence: 99%

From bench to bedside, work in cell-based myocardial regeneration therapy

Miyagawa

Sawa²

2014

JBiSE

View full text Add to dashboard Cite

In clinical cellular cardiomyoplasty, bone marrow cells and myoblasts are introduced mainly to ischemic cardiomyopathy tissue via several cell delivery systems, such as needle injection or catheter. These clinical studies have demonstrated the safety and feasibility of this technique, but its effectiveness for treating heart failure, especially in the long term, is still under discussion. Neither of these cell types can differentiate into cardiomyocytes; rather, they improve the failing heart mainly by the paracrine effects of some cytokines, such as Hepatocyte growth factor (HGF) and Vascular endothelial growth factor (VEGF). Thus, many researchers have a great interest in stem cells, which exist in bone marrow, circulating blood, atrium, and adipose tissue, and can differentiate into cardiomyocytes. Although several stem cells with the potential to differentiate into various cell types have been reported, few can differentiate into cardiomyocytes. Moreover, beating cells that can demonstrate synchronized contraction with native cardiomyocytes are critical for the complete repair of severe heart failure. Therefore, stem cells with a high differentiation capacity should be explored for the goal of completely repairing severely damaged myocardium. In this review, we summarize the clinical protocols and basic experiments for cellular cardiomyoplasty using bone marrow cells, myoblasts, and other stem cells.

show abstract

Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat

Cited by 134 publications

References 31 publications

Human Amniotic Fluid Stem Cells Do Not Differentiate Into Dopamine Neurons In Vitro or After Transplantation In Vivo

Human Amniotic Fluid Stem Cells Do Not Differentiate Into Dopamine Neurons In Vitro or After Transplantation In Vivo

Concise Review: Culture Mediated Changes in Fate and/or Potency of Stem Cells

From bench to bedside, work in cell-based myocardial regeneration therapy

Contact Info

Product

Resources

About